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Abstract
The co-inhibitory immune receptor carcinoembryonic antigen-related cell-adhesion molecule 1 (CEACAM1) and its
self-ligand CEACAM1 can suppress T cell function. Suppression of T cell function in sepsis is well documented. Late-
onset neonatal sepsis in VLBW-infants was associated with an increased percentage CEACAM1 positive CD4+ T-
cells. Meningococcal septic shock in children was associated with increased serum soluble CEACAM1. In conclusion
our data demonstrate increased surface expression of the co-inhibitory immune receptor CEACAM1 in late-onset
neonatal sepsis in VLBW-infants, and increased circulating soluble CEACAM1 in children with meningococcal sepsis.
Increased T-cell CEACAM1 expression and increased circulating soluble CEACAM1 may contribute to sepsis-
associated immune suppression.
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Introduction
Sepsis is defined as a systemic inflammatory syndrome in
response to an infection. Sepsis is an important cause of
pediatric morbidity and mortality [1]. The host inflammatory
response in sepsis is characterized by aspects of both a
hyperactive immune response and immunosuppression [2].
Suppression of T-cell function and T-cell apoptosis in sepsis is
well documented [2–4]. The mechanism of T-cell suppression
is, however, not fully understood. Immune co-receptors on
myeloid and lymphoid cells modulate the response of immune
activating receptors and are crucial in regulating inflammation
[5,6]. Recent data support an important role of costimulatory
molecules in the regulation of inflammation in severe sepsis,
and demonstrate an increase in the percentage CD4+ T-cells
expressing the immune inhibitory receptor cytotoxic T
lymphocyte antigen-4 (CTLA-4) [7,8].
[5,6]The carcinoembryonic antigen-related cell-adhesion
molecule 1 (CEACAM1) has recently been recognized as a
regulatory co-receptor for both myeloid and lymphoid cell types
[9]. Most studies have ascribed an inhibitory function to
CEACAM1 in T-cells. Ligation of CEACAM1 on T cells induces
a signal cascade that leads to suppression of T cell cytokine
production and proliferation [10,11]. In vitro activation of T-cells
by cytokines such as IL-2, IL-7 and IL-15 causes rapid and
strong CEACAM1 up regulation, which persists for many days
[12]. CEACAM1 is activated by its self-ligand CEACAM1.
We hypothesized upregulation of CEACAM1 occurs in
sepsis. Firstly we tested whether CD4+ T-cell CEACAM1
expression is increased in very low birthweight (VLBW) infants
(birth weight 401-1500 gram) with late-onset neonatal sepsis.
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Secondly, we tested whether serum soluble CEACAM1
concentration is increased in children with meningococcal
septic shock. Our results demonstrate for the first time that
CEACAM 1 is increased in sepsis.
Methods
Patients and controls
Ethics statement.  The medical ethics committee of the
Erasmus University Medical Center Rotterdam and University
Medical Center Utrecht approved the study protocols and
written informed consent was obtained from parents or legal
representatives of children. For the use of surplus blood
samples in control very-low birth weight infants verbal consent
from parents or legal representatives of children was obtained.
No written consent was deemed necessarily for the use of
surplus blood samples by the ethics committee, all parents
received written information on the use of surplus blood
samples for research purposes and were asked if they agreed.
The medical ethics committee of the Erasmus University
Medical Center Rotterdam approved this procedure.
Two groups of pediatric sepsis patient were studied: very-low
birthweight (VLBW) infants with late-onset neonatal sepsis and
children with meningococcal sepsis. The reported studies have
an exploratory nature, hence no power calculation was
performed.
Neonatal sepsis sub study.  In the neonatal sepsis group
twelve very-low birthweight infants with late-onset neonatal
sepsis were included between April and September 2008, at
the Neonatal Intensive Care Unit (NICU) of the Sophia
Children’s Hospital, Erasmus Medical Centre. Etiologic agents
were Escherichia coli (n=2), coagulase negative
staphylococcus (n=6), no pathogen isolated n=4). The group
size of the late-onset sepsis group was determined by study
enrollment of consecutive late-onset sepsis cases during the
study period and arbitrary the minimal number of controls was
set on 16.
Neonatal sepsis was defined as a bloodstream infection
following a previously published definition for culture confirmed
and clinical bloodstream infection in (premature) neonates [13].
For the diagnosis of clinical bloodstream infection we added
the presence of a raised serial CRP as a third requirement (At
an interval >12 hours following initial blood sample at onset of
sepsis, CRP >10 mg/L or CRP further increased compared to
initial sample if elevated CRP present at sepsis onset). Late-
onset neonatal sepsis was defined as neonatal sepsis with
onset > 48 hours after birth. The control group consisted of
sixteen VLBW infants without sepsis admitted to the NICU
during the same period.
Meningococcal sepsis sub study.  In the meningococcal
sepsis group we included twenty-eight patients with
meningococcal septic shock of whom stored blood samples
were available. All patients were enrolled in a clinical trial of
activated protein C between July 1997 and February 2000 at
the Pediatric Intensive Care Unit (PICU) of the Sophia
Children’s Hospital, Erasmus Medical Centre [14]. The number
of cases in the meningococcal sepsis group was determined by
number of patients of whom of stored frozen serum samples
were available (28 of 40). Meningococcal sepsis was defined
as described previously in accordance with the
recommendations of the international Pediatric Sepsis
Consensus Conference, Neisseria meningitidis was isolated
from blood in 26/28 (92%) [14,15]. In the control group for the
meningococcal sepsis study we included sixteen patients, who
had presented at the emergency room with fever for whom a
diagnosis of meningitis was excluded by lumbar puncture and
of whom stored blood samples were available. All control
patients were enrolled between January 1998 and January
2000 at the University Medical center Utrecht [16]. The number
of controls in the meningococcal sepsis control group was
determined by number of patients of whom of stored frozen
serum samples were available (16 of 18). For all children in the
control group severe bacterial infection was ruled out, and all
were diagnosed tentatively as “viral illness”.
Clinical and laboratory data.  Clinical characteristics,
disease severity scores (Score for Neonatal Acute Physiology
(SNAP) II, Pediatric Risk of Mortality (PRISM) III), and
laboratory parameters including CRP at sepsis onset and peak
CRP (maximal CRP values during the same sepsis episode)
were collected from medical records and a computerized
patient data information system at study entry and during the
course of the disease. Serum CRP levels were measured by a
nephelometric assay, normal levels are less than 10 mg/L.
Patients were monitored for 28 days or until death or hospital
discharge.
Sample collection and CEACAM1 measurement
Neonatal sepsis sub study.  In late-onset neonatal sepsis
patients blood was collected in lithium heparine or EDTA tubes
median at 32 hours (range 20-122 hours; in 9 patients at
20-36h) after sepsis onset (lithium heparine samples in 3/12
infants with sepsis versus 2/16 controls). We determined
CEACAM1 expression on the CD4+ T cells by flow cytometry.
Before the start of the study it was established that
measurement in lithium heparin or EDTA samples did not result
in different CEACAM1 expression values (data not shown).
Fresh samples were analyzed, fifty microliter whole blood
samples were transferred to 50 ml tubes (Falcon, BD
biosciences). The red blood cells were then lysed and the cells
were then labeled with the following antibodies CD3 (SK7; BD
biosciences; 1:5), CD4 (SK3; BD biosciences; 1:50), and
CD66a/CEACAM1 (283340; R&D Systems; 10μL to 100,000
cells) at for 20 minutes in the dark on ice. After being washed 3
times the cells were fixed with 0.1% paraformaldehyde and
analyzed on a BD four-color flow cytometer (BD Bio-sciences)
and analyzed with Cell quest software. Lymphocytes were
identified by CD3/CD4 labeling. A minimum of 10,000
leukocytes/sample were measured. No absolute numbers of
CEACAM1 expressing CD4+ T cells was determined, only the
percentage CD4+ T cells expressing CEACAM1.
Meningococcal sepsis sub study.  In meningococcal
sepsis patients serum samples were collected at ICU
admission, 24-48 hours, 7-8 days and 3 months. Serum
samples in the meningococcal sepsis control group were
collected at the time of initial emergency room presentation
with fever. Serum samples were stored at -80 oC. Soluble
CEACAM1 in Sepsis
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CEACAM1 in serum was determined by a commercially
available immunoassay (DY2244, R&D Systems) and
performed according to the manufacturer’s specifications. In
addition to determining the absolute concentration of soluble
CEACAM1 in serum we also calculated the magnitude of
change in sequential samples of individual patients at different
time points when compared to serum soluble CEACAM1
concentrations on PICU admission.
Statistical analysis
Data are expressed as mean ± standard deviation, unless
stated otherwise. Comparisons between groups were analyzed
by the Students t-test or one-way ANOVA with Bonferoni
correction where appropriate. Correlations were tested by
Pearson’s correlation coefficients. Differences were considered
statistically significant when P <0.05. Correlations of
CEACAM1 expression with maximal CRP or disease severity
scores were tested one-sided, all other tests were two-sided.
Results
Neonatal sepsis sub study
Characteristics of the patients and controls are shown in
Table 1. The percentage CEACAM1 positive CD4+ T-cells in
the late-onset sepsis group were higher than in the VLBW
infant control group (26.8% ± 24.0 versus 12.0% ± 13.0;
P=0.046; see Figure 1A).
Sepsis associated mortality was 1/12 (8.3%). The
percentage CEACAM1 positive CD4+ T-cells in VLBW infants
was not related to gestational age, antenatal steroids, and time
of sampling after sepsis onset. The peak CRP level 70 mg/L ±
63 as a measure of acute phase response and inflammation
showed a moderate but significant correlation with percentage
Table 1. Characteristics of patients and controls.
late-onset neonatal sepsis substudy sepsis patients controls
 (n=12) (n=16)
Male/female ratio 6/6 10/6
Birthweight (g) 1258 (650-1465) 955 (640-1465)
Gestational age at birth (weeks) 28.9 (26.4-31.0) 27.3 (25.1-33.3)
Gestational age at sepsis onset/blood
sampling (w) 30.6 (27.6-36.9) 28.4 (26.6-36.1)
SNAP II at sepsis onset/blood sampling 4 (0-32) 3 (0-29)
CRP at sepsis onset (mg/L) 15 (1-123) 1 (1-6)
Peak CRP (mg/L) 61 (1-228) 2 (1-9)
meningococcal sepsis substudy sepsis patients controls
 (n=28) (n=16)
Male/female ratio 16/12 12/4
Age (years) 2.3 (0.3-16) 1.0 (0.1-14)
PRISM III score 24 ± 9  
CRP at sepsis onset (mg/L) 76 ± 48  
Peak CRP (mg/L) 174 ± 92  
Male/female ratio data are numbers of patients; birthweight and age data are
median (range); all other data are mean ± standard deviation
CEACAM1 positive CD4+ T-cells in sepsis patients (R=0.553,
P =0.031; see Figure 2).
Meningococcal sepsis sub study
Characteristics of the patients and controls are shown in
Table 1. Serum soluble CEACAM1 concentrations were not
elevated in meningococcal septic shock patients at PICU
admission.
Serum soluble CEACAM1 concentrations at 24-48 hours
were significantly elevated compared to controls and values at
ICU admission respectively (70.4 ng/mL ± 52.6 versus 14.0
ng/mL ± 7.9 versus 13.5 ng/mL ± 12,9; P < 0.05; see Figure
1B).
Soluble CEACAM1 levels were not associated with
administration of the trial drug activated protein C (data not
shown). Serum soluble CEACAM1 concentrations were not
correlated with disease severity measured by PRISM score or
peak CRP.
Septic shock associated mortality was 8/28 (27%), Seven
deaths occurred within the first 24 hours following ICU
admission, one death within 48 hours following ICU admission.
Soluble CEACAM1 levels on ICU admission were not different
for survivors and non-survivors (14.4 ng/mL ± 15.0 versus 10.9
ng/mL ± 4.1; P= 0.16), and the 24-48h values in survivors were
comparable to the 24 hour serum concentration of soluble
CEACAM1 in the single patient that died after the first 24 hours
following ICU admission (70.6 ng/mL ± 54.0 versus 65.6 ng/
mL).
Soluble CEACAM1 levels were persistently elevated at day
7-8 (50.2 ng/mL ± 12.9; P < 0.05), but had returned to normal
values in convalescent serum samples drawn 3 months after
sepsis onset (15.7 ng/mL ± 12.3; see Figure 1B). Analysis of
the magnitude of change of serum soluble CEACAM1
concentrations in comparison to individual PICU admission
values was consistent with analysis of absolute values (24-48h:
569% ± 173; P < 0.05; day 7-8: 483% ± 253; P< 0.05; 3
months: 159% ± 170; P=0.2).
Discussion
The primary finding in this study suggests that late-onset
neonatal sepsis in VLBW-infants causes an increase in the
percentage circulating CD4+ T-cells expressing CEACAM1. In
addition, our data show meningococcal septic shock is
associated with a significant and persistent increase in
circulating soluble CEACAM1 concentration from 24–48hours
up to day 7-8 following PICU admittance.
In the VLBW infants with late-onset neonatal sepsis
CEACAM1 expression on the CD4+ T-cells correlated with the
maximal CRP levels, while in children with meningococcal
septic shock serum soluble CEACAM1 concentrations did not
correlate with CRP. In the present study we did not assess the
absolute numbers of CD4+ T-cells, thus we cannot determine
whether the observed increase is relative or absolute. Effect of
treatment in the ICU (e.g. antibiotics, vasopressive drugs) on
CEACAM1 levels cannot be excluded from our study. No
correlation between the percentage CEACAM1 positive CD4+
T-cells or levels of soluble CEACAM1 and clinical disease
CEACAM1 in Sepsis
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severity scores was demonstrated. Our study was limited in
size and larger studies to confirm our findings also in different
age groups and in patients with different sepsis etiologies are
warranted.
The CEACAM1 molecule in humans displays considerable
variation, 11 different CEACAM1 splice variants have been
detected. Splice variants differ in the number of extracellular
immunoglobulin-like domains, membrane anchorage, and also
the length of their cytoplasmic tails. Splice variants in
transmembrane and intracellular domains have functional
significance. Isotypes with short cytoplasmic tails lack inhibitory
function. Regulation of expression of different isotypes can vary
with cellular activation state. In general long cytoplasmic tail
isotypes are more abundant and CEACAM1 is generally seen
as an inhibitory immune co-receptor [9].
Figure 1.  Expression of Carcinoembryonic antigen-related cell-adhesion molecule 1 (CEACAM1) in sepsis.  A. Percentage
CEACAM1 positive CD4+ T cells as determined by flow cytometric analysis in very low birth weight infants with late-onset neonatal
sepsis (n=12) and non-septic controls (n=16). Data were analyzed by the Students t-test. Asterix indicates P<0.05. B
Concentrations of serum soluble CEACAM1 in children with meningococcal septic shock (T0h n=28; T24-48h n=20; T7-8d n=11; T3M n=6)
compared to healthy controls (n=16). Concentrations of soluble CEACAM1 were measured by ELISA. Levels were higher in children
with septic shock at 24-48h and elevated levels persisted at day 7-8. Differences were analyzed by one-way ANOVA with Bonferoni
correction. Asterix indicates P<0.05. Data are expressed as mean ± standard error.
doi: 10.1371/journal.pone.0068294.g001
CEACAM1 in Sepsis
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Not surface expressed, but soluble isotypes of CEACAM1
also mediate biological functions, by activation of surface
expressed CEACAM1, or by interference with binding of
CEACAM1 to other surface expressed CEACAM1 molecules.
In the present study we did not address the variation
introduced by CEACAM1 splice variants. It will be valuable to
assess in future studies and to assess the relative expression
of functionally different CEACAM1 isoforms.
Consistent with findings in human adults, CEACAM1 was
expressed on a low percentage human peripheral-blood CD4+
T-cells in non-septic VLBW-infants [9]. Certain pathologic
conditions (coeliac disease and inflammatory bowel disease)
have previously been shown to cause increased CEACAM1
expression on T cells in the lamina propria of the gut [12,17]. In
vitro activation of T-cells by cytokines such as IL-2, IL-7 and
IL-15 causes rapid and strong CEACAM1 up regulation, which
persists for many days. At present there is debate on the role
of these cytokines in sepsis in vivo, and the potential
mechanism by which these cytokines may prevent immune
dysfunction (Please see also comment on reference 18 and 19
by E.D. Carrol J Immunol 2010) [18,19]. [12,17]
We are the first to demonstrate an increase in CEACAM1
positive CD4+ T-cells in peripheral blood in vivo in humans in
sepsis. Since CEACAM1 generally functions as an inhibitor of
T-cell receptor activation, increased CD4+ T-cells CEACAM1
expression in sepsis may contribute to the suppression of T cell
functions as observed in sepsis. Soluble CEACAM1 may
function as a ligand for CEACAM1 and thus altered
concentrations of soluble CEACAM1 in sepsis may further
influence T-cell functions. Furthermore CEACAM1 is also
expressed on innate immune cells, such as neutrophils,
monocytes, and natutal killer cells, and altered soluble
CEACAM1 concentrations in sepsis may directly influence
neutrophil and monocyte survival [20,21]. In addition soluble
CEACAM1 may interfere with CEACAM1 mediated cell-cell
contact and thus influence immune regulation, as
demonstrated for natural killer cells [22].
CEACAM1 is also reported to inhibit Toll-like Receptor-2
signaling and Toll-like Receptor-4, thus increased circulating
Figure 2.  Percentage CEACAM1 positive CD4+ T-cells correlate with Peak CRP.  Data represent Peak CRP levels during the
course of sepsis and Percentage CEACAM1 positive CD4+ T-cells at a median of 32 hours (range 20-122 hours) after sepsis onset
in late-onset neonatal sepsis in VLBM-infants. Linear regression line is drawn. Higher Peak CRP levels correlate with higher
percentage CEACAM1 positive CD4+ T-cells (Pearson’s correlation coefficient R= 0.553; P < 0.05).
doi: 10.1371/journal.pone.0068294.g002
CEACAM1 in Sepsis
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soluble CEACAM1 might contribute to inhibition of Toll-like
Receptor responses in sepsis [23,24].
Interestingly, in genetically engineered mice that are
resistant to apoptosis due to transfection with the anti-
apoptosis gene Bcl-2, sepsis results in uniquely decreased
transcription of CEACAM1 in splenocytes and increased sepsis
survival [25]. Whether a decrease in splenocyte CEACAM1
expression improves sepsis survival, or whether there is no
causal relation, is unknown.
From our data we can not exclude that the increase in
percentage CEACAM1 positive CD4+ T-cells is caused by a
greater loss of CEACAM1 negative CD4+ T-cells for instance
by apoptosis.
It will be valuable to determine whether sepsis causes a
relative or absolute increase in CEACAM1 expressing CD4+ T-
cells in future studies. Further determination of the functional
role of CEACAM1 in sepsis seems justified, as targeting
CEACAM1 might be of potential therapeutic benefit in sepsis.
Pathogens including Neisseria meningitides also bind
CEACAM1 and current data on immune modulating effects of
such interactions are conflicting [9,26,27]. Thus circulating
soluble CEACAM1 in children with meningococcal sepsis may
also bind whole bacterial cells or blebs in the circulation and
might further affect the immune response to meningococci.
Further research will be needed to evaluate the effects of such
interactions on the immune response and overall course of
disease.
In conclusion our data demonstrate increased surface
expression of the co-inhibitory immune receptor CEACAM1 in
late-onset neonatal sepsis in VLBW-infants, and increased
circulating CEACAM1 self-ligand soluble CEACAM1 in children
with meningococcal sepsis. Increased T-cell CEACAM1
expression and increased circulating soluble CEACAM1 may
contribute to sepsis-associated immune suppression.
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